🎉 M&A multiples are live!
Check it out!

Marksans Pharma Valuation Multiples

Discover revenue and EBITDA valuation multiples for Marksans Pharma and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Marksans Pharma Overview

About Marksans Pharma

Marksans Pharma Ltd is a pharmaceutical company. The company is engaged in the research, manufacturing, and marketing of pharmaceutical formulations. It manufactures analgesics, gastroenterology, anti-diabetic, cardiovascular, pain management, gynecology, gastrointestinal, and oncologic drugs as well as antibiotics and antiallergic medications. Geographically, the majority of its revenue is generated from the United States and North America, followed by Europe and the UK, Australia and New Zealand, and the Rest of the World.


Founded

1992

HQ

India
Employees

815

Financials

LTM Revenue $306M

LTM EBITDA $63.2M

EV

$1.0B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Marksans Pharma Financials

Marksans Pharma has a last 12-month revenue of $306M and a last 12-month EBITDA of $63.2M.

In the most recent fiscal year, Marksans Pharma achieved revenue of $253M and an EBITDA of $59.1M.

Marksans Pharma expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Marksans Pharma valuation multiples based on analyst estimates

Marksans Pharma P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $215M $253M XXX XXX XXX
Gross Profit $85.0M $108M XXX XXX XXX
Gross Margin 40% 43% XXX XXX XXX
EBITDA $45.9M $59.1M XXX XXX XXX
EBITDA Margin 21% 23% XXX XXX XXX
Net Profit $21.7M $30.9M XXX XXX XXX
Net Margin 10% 12% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Marksans Pharma Stock Performance

As of April 15, 2025, Marksans Pharma's stock price is INR 206 (or $2).

Marksans Pharma has current market cap of INR 93.2B (or $1.1B), and EV of INR 88.3B (or $1.0B).

See Marksans Pharma trading valuation data

Marksans Pharma Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$1.0B $1.1B XXX XXX XXX XXX $0.10

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Marksans Pharma Valuation Multiples

As of April 15, 2025, Marksans Pharma has market cap of $1.1B and EV of $1.0B.

Marksans Pharma's trades at 3.4x LTM EV/Revenue multiple, and 16.2x LTM EBITDA.

Analysts estimate Marksans Pharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Marksans Pharma and 10K+ public comps

Marksans Pharma Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $1.0B XXX XXX XXX
EV/Revenue 3.5x XXX XXX XXX
EV/EBITDA 16.6x XXX XXX XXX
P/E 25.7x XXX XXX XXX
P/E/Growth 1.0x XXX XXX XXX
EV/FCF 51.4x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Marksans Pharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Marksans Pharma Valuation Multiples

Marksans Pharma's NTM/LTM revenue growth is 18%

Marksans Pharma's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.1M for the same period.

Over next 12 months, Marksans Pharma's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Marksans Pharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Marksans Pharma and other 10K+ public comps

Marksans Pharma Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 18% XXX XXX XXX XXX
EBITDA Margin 21% XXX XXX XXX XXX
EBITDA Growth 29% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 39% XXX XXX XXX XXX
Revenue per Employee $0.3M XXX XXX XXX XXX
Opex per Employee $0.1M XXX XXX XXX XXX
S&M Expenses to Revenue 6% XXX XXX XXX XXX
G&A Expenses to Revenue 1% XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue 32% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Marksans Pharma Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Marksans Pharma M&A and Investment Activity

Marksans Pharma acquired  XXX companies to date.

Last acquisition by Marksans Pharma was  XXXXXXXX, XXXXX XXXXX XXXXXX . Marksans Pharma acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Marksans Pharma

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Marksans Pharma

When was Marksans Pharma founded? Marksans Pharma was founded in 1992.
Where is Marksans Pharma headquartered? Marksans Pharma is headquartered in India.
How many employees does Marksans Pharma have? As of today, Marksans Pharma has 815 employees.
Is Marksans Pharma publicy listed? Yes, Marksans Pharma is a public company listed on NSE.
What is the stock symbol of Marksans Pharma? Marksans Pharma trades under MARKSANS ticker.
When did Marksans Pharma go public? Marksans Pharma went public in 2002.
Who are competitors of Marksans Pharma? Similar companies to Marksans Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Marksans Pharma? Marksans Pharma's current market cap is $1.1B
What is the current revenue of Marksans Pharma? Marksans Pharma's last 12-month revenue is $306M.
What is the current EBITDA of Marksans Pharma? Marksans Pharma's last 12-month EBITDA is $63.2M.
What is the current EV/Revenue multiple of Marksans Pharma? Current revenue multiple of Marksans Pharma is 3.4x.
What is the current EV/EBITDA multiple of Marksans Pharma? Current EBITDA multiple of Marksans Pharma is 16.2x.
What is the current revenue growth of Marksans Pharma? Marksans Pharma revenue growth between 2023 and 2024 was 18%.
Is Marksans Pharma profitable? Yes, Marksans Pharma is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.